6-Hydroxydopamine hydrobromideSelective catecholaminergic neurotoxin CAS# 636-00-0 |
- Edoxaban tosylate monohydrate
Catalog No.:BCC1545
CAS No.:1229194-11-9
- Otamixaban
Catalog No.:BCC1827
CAS No.:193153-04-7
- Betrixaban
Catalog No.:BCC5118
CAS No.:330942-05-7
- Rivaroxaban
Catalog No.:BCC2292
CAS No.:366789-02-8
- Edoxaban
Catalog No.:BCC1543
CAS No.:480449-70-5
- Apixaban
Catalog No.:BCC2295
CAS No.:503612-47-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 636-00-0 | SDF | Download SDF |
PubChem ID | 176170 | Appearance | Powder |
Formula | C8H12BrNO3 | M.Wt | 250.09 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | 6-OHDA | ||
Solubility | DMSO : ≥ 100 mg/mL (399.86 mM) H2O : 20 mg/mL (79.97 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 5-(2-aminoethyl)benzene-1,2,4-triol;hydrobromide | ||
SMILES | C1=C(C(=CC(=C1O)O)O)CCN.Br | ||
Standard InChIKey | MLACDGUOKDOLGC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H11NO3.BrH/c9-2-1-5-3-7(11)8(12)4-6(5)10;/h3-4,10-12H,1-2,9H2;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective catecholaminergic neurotoxin. Depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons. Causes almost complete destruction of nigral dopaminergic neurons and their striatal terminals when injected into the substantia nigra of rats, producing an animal model of Parkinson's disease. |
6-Hydroxydopamine hydrobromide Dilution Calculator
6-Hydroxydopamine hydrobromide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.9986 mL | 19.9928 mL | 39.9856 mL | 79.9712 mL | 99.964 mL |
5 mM | 0.7997 mL | 3.9986 mL | 7.9971 mL | 15.9942 mL | 19.9928 mL |
10 mM | 0.3999 mL | 1.9993 mL | 3.9986 mL | 7.9971 mL | 9.9964 mL |
50 mM | 0.08 mL | 0.3999 mL | 0.7997 mL | 1.5994 mL | 1.9993 mL |
100 mM | 0.04 mL | 0.1999 mL | 0.3999 mL | 0.7997 mL | 0.9996 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxidopamine hydrobromide is a selective catecholaminergic neurotoxin, depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons. In vitro: Oxidopamine hydrobromide-induced apoptosis of PC12 cells was initiated by superoxide generation followed by caspase cascade activation, which was associated with the suppressed Akt phosphorylation and increased p38 phosphorylation. It is likely that pCPT-cAMP prevented the Oxidopamine hydrobromide-induced apoptosis via activation of the PI3-kinase/Akt pathway without any effect on superoxide generation or mitochondrial membrane depolarization. [1] In vivo the presence of sulfhydryl antioxidants protected against neuronal degeneration in the striatum, which was particularly remarkable in the case of CySH and was attributed to its capacity to remove the H2O2 produced in the autoxidation of Oxidopamine hydrobromide.
References:
[1]. Fujita H et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 Oct 3;1113(1):10-23.
[2]. Soto-Otero R et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000 Apr;74(4):1605-12.
- Terazosin
Catalog No.:BCC5162
CAS No.:63590-64-7
- Foscarnet Sodium
Catalog No.:BCC4782
CAS No.:63585-09-1
- Darunavir Ethanolate
Catalog No.:BCC5627
CAS No.:635728-49-3
- Pazopanib Hydrochloride
Catalog No.:BCC3708
CAS No.:635702-64-6
- Microhelenin C
Catalog No.:BCN7977
CAS No.:63569-07-3
- 8-Benzoyl-5,7-dihydroxy-2,2-dimethylchromane
Catalog No.:BCN1389
CAS No.:63565-07-1
- Rebaudioside C
Catalog No.:BCN2404
CAS No.:63550-99-2
- Adrafinil
Catalog No.:BCC4166
CAS No.:63547-13-7
- 24,25-Dihydroxydammar-20-en-3-one
Catalog No.:BCN4174
CAS No.:63543-53-3
- 24,25-Epoxydammar-20(21)-en-3-one
Catalog No.:BCN4173
CAS No.:63543-52-2
- LY404039
Catalog No.:BCC4592
CAS No.:635318-11-5
- 4,2'-Dihydroxy-4'-methoxychalcone
Catalog No.:BCN7704
CAS No.:63529-06-6
- D-(+)-Maltose monohydrate
Catalog No.:BCN8423
CAS No.:6363-53-7
- DADLE
Catalog No.:BCC6064
CAS No.:63631-40-3
- Coniferyl ferulate
Catalog No.:BCN8543
CAS No.:63644-62-2
- 1,5-Bis(4-hydroxy-3-methoxyphenyl)penta-1,4-diene
Catalog No.:BCN1388
CAS No.:63644-68-8
- Gamma-Methoxyisoeugenol
Catalog No.:BCN3999
CAS No.:63644-71-3
- Z-D-Glu-OH
Catalog No.:BCC2775
CAS No.:63648-73-7
- Betaxolol HCl
Catalog No.:BCC4343
CAS No.:63659-19-8
- H-Lys(Z)-OBzl.HCl
Catalog No.:BCC2987
CAS No.:6366-70-7
- H-D-Asp-Obzl
Catalog No.:BCC2895
CAS No.:6367-42-6
- Nisoldipine
Catalog No.:BCC4809
CAS No.:63675-72-9
- Boc-D-Ser-OH
Catalog No.:BCC3447
CAS No.:6368-20-3
- Clofibrate
Catalog No.:BCC5308
CAS No.:637-07-0
Animal models of Parkinsons disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).[Pubmed:25936513]
Eur J Pharmacol. 2015 Aug 15;761:353-61.
Antagonism of the adenosine A2A receptor represents a promising strategy for non-dopaminergic treatment of Parkinsons disease (PD). Previously, the adenosine A2A receptor antagonist ST1535 was shown to possess potential beneficial effects in animal models of PD. Two metabolites of ST1535, namely ST3932 and ST4206, were tested in vitro to assess their affinity and activity on cloned human A2A adenosine receptors, and their metabolic profile. Additionally, ST3932 and ST4206 were investigated in vivo in animal models of PD following oral/intraperitoneal administration of 10, 20 and 40mg/kg using ST1535 as a reference compound. ST3932 and ST4206 displayed high affinity and antagonist behaviour for cloned human adenosine A2A receptors. The Ki values for ST1535, ST3932 and ST4206 were 8, 8 and 12nM, respectively, and their IC50 values on cyclic AMP were 427, 450 and 990nM, respectively. ST1535, ST3932 and ST4206 antagonized (orally) haloperidol-induced catalepsy in mice, potentiated (intraperitoneally) the number of contralateral rotations induced by l-3,4-dihydroxyphenylalanine (l-DOPA) (3mg/kg) plus benserazide (6mg/kg) in 6-Hydroxydopamine hydrobromide (6-OHDA)-lesioned rats, and increased mouse motor activity by oral route. Thus, ST3932 and ST4206, two ST1535 metabolites, show a pharmacological activity similar to ST1535, both in vitro and in vivo, and may be regarded as an interesting pharmacological alternative to ST1535.
Roles of dopaminergic innervation of nucleus accumbens shell and dorsolateral caudate-putamen in cue-induced morphine seeking after prolonged abstinence and the underlying D1- and D2-like receptor mechanisms in rats.[Pubmed:23151613]
J Psychopharmacol. 2013 Feb;27(2):181-91.
Drug-associated cues can elicit relapse to drug seeking after abstinence. Studies with extinction-reinstatement models implicate dopamine (DA) in the nucleus accumbens shell (NAshell) and dorsolateral caudate-putamen (dlCPu) in cocaine seeking. However, less is known about their roles in cue-induced opiate seeking after prolonged abstinence. Using a morphine self-administration and abstinence-relapse model, we explored the roles of NAshell and dlCPu DA and the D1/D2-like receptor mechanisms underlying morphine rewarding and/or seeking. Acquisition of morphine self-administration was examined following 6-Hydroxydopamine hydrobromide (6-OHDA) lesions of the NAshell and dlCPu. For morphine seeking, rats underwent 3 weeks' morphine self-administration followed by 3 weeks' abstinence from morphine and the training environment. Prior to testing, 6-OHDA, D1 antagonist SCH23390, or D2 antagonist eticlopride was locally injected; then rats were exposed to morphine-associated contextual and discrete cues. Results show that acquisition of morphine self-administration was inhibited by NAshell (not dlCPu) lesions, while morphine seeking was attenuated by lesions of either region, by D1 (not D2) receptor blockade in NAshell, or by blockade of either D1 or D2 receptors in dlCPu. These data indicate a critical role of dopaminergic transmission in the NAshell (via D1-like receptors) and dlCPu (via D1- and D2-like receptors) in morphine seeking after prolonged abstinence.
Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway.[Pubmed:16945353]
Brain Res. 2006 Oct 3;1113(1):10-23.
Although cAMP protects neuronal cells from various apoptotic stimulations, its mechanism is not fully elucidated. We report here the molecular mechanism of the 6-hydroxydopamine (6-OHDA)-induced apoptosis of pheochromocytoma PC12 cells and its suppression by 8-(4-chlorophenylthio)adenosine 3',5'-cyclic monophosphate (pCPT-cAMP), which is a membrane permeable cAMP analog. Treatment of PC12 cells with 6-OHDA resulted in the activation of caspases and apoptosis, as detected by chromatin condensation. 6-OHDA also induced superoxide generation, Bid cleavage and mitochondrial membrane depolarization. In addition, Akt phosphorylation that was favorable to cell survival was decreased and p38 MAPK phosphorylation was increased by 6-OHDA. PC12 cell apoptosis was inhibited by pCPT-cAMP, Z-VAD-fmk (a broad-range caspase inhibitor) and tiron (a superoxide scavenger), although PC12 cell apoptosis was not inhibited by cyclosporine A (an inhibitor of mitochondrial membrane permeability transition). Moreover, pCPT-cAMP promoted Akt phosphorylation, but it did not prevent superoxide generation and mitochondrial membrane depolarization. Conversely, LY294002, an inhibitor of Akt upstream molecule PI3-kinase, enhanced 6-OHDA-induced apoptosis. These results indicated that the 6-OHDA-induced apoptosis of PC12 cells was initiated by superoxide generation followed by caspase cascade activation, which was associated with the suppressed Akt phosphorylation and increased p38 phosphorylation. It is likely that pCPT-cAMP prevented the 6-OHDA-induced apoptosis via activation of the PI3-kinase/Akt pathway without any effect on superoxide generation or mitochondrial membrane depolarization.
Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.[Pubmed:10737618]
J Neurochem. 2000 Apr;74(4):1605-12.
6-Hydroxydopamine (6-OHDA) is a dopaminergic neurotoxin putatively involved in the pathogenesis of Parkinson's disease (PD). Its neurotoxicity has been related to the production of reactive oxygen species. In this study we examine the effects of the antioxidants ascorbic acid (AA), glutathione (GSH), cysteine (CySH), and N-acetyl-CySH (NAC) on the autoxidation and neurotoxicity of 6-OHDA. In vitro, the autoxidation of 6-OHDA proceeds rapidly with the formation of H2O2 and with the participation of the H2O2 produced in the reaction. The presence of AA induced a reduction in the consumption of O2 during the autoxidation of 6-OHDA and a negligible presence of the p-quinone, which demonstrates the efficiency of AA to act as a redox cycling agent. The presence of GSH, CySH, and NAC produced a significant reduction in the autoxidation of 6-OHDA. In vivo, the presence of sulfhydryl antioxidants protected against neuronal degeneration in the striatum, which was particularly remarkable in the case of CySH and was attributed to its capacity to remove the H2O2 produced in the autoxidation of 6-OHDA. These results corroborate the involvement of oxidative stress as the major mechanism in the neurotoxicity of 6-OHDA and the putative role of CySH as a scavenger in relation to PD.